Clinical Trials

Open for Recruitment:

Patients with urothelial carcinoma receiving neoadjuvant therapy or patients with cancer receiving standard of care anti-PD-1/L1: Principal Investigator - Dr. Larry Fong at UCSF
This is a single-center cross-sectional imaging study in patients with urothelial cancer undergoing neoadjuvant therapy, and patients with advanced cancer receiving standard of care (SOC) anti-PD-1 or anti-PD-L1. Study participants will undergo whole body PET(Positron Emission Tomography)/MR(Magnetic Resonance) imaging with VisAcT/[18F]F-AraG prior to initiating therapy and at a timepoint post initiation of treatment.

Patients with squamous cell carcinoma of the head and neck who will undergo treatment with anti-PD-1 treatment: Principal Investigator - Dr. Dimitri Colevas at Stanford University
This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1 treatment prior to tumor resection or radiation. Patients will undergo two whole body PET(Positron Emission Tomography)/CT(Computed Tomography) imaging with VisAcT/[18F]F-AraG. First scan prior to initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment.

Patients with localized non small cell lung cancer undergoing immunotherapy with or without stereotactic radiation therapy: Prinicpal Investigator - Dr. Ben Franc at UCSF
This is a single-center cross-sectional imaging study in patients with localized non-small cell lung cancer (NSCLC) and is part of the companion clinical trial (NCT03217071; Pembrolizumab with and without radiotherapy). Study participants will undergo a single whole body PET(Positron Emission Tomography)/CT (computed tomography) scan with VisAcT/[18F]F-AraG. The companion trial is for patients with stage I-IIIA NSCLC who will receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy to the lateral half of the primary lung tumor prior to resection.

Patients with solid tumors eligible to undergo immunotherapy treatment: Principal Investigator - Dr. Henry VanBrocklin at UCSF
This is an exploratory study to assess the biodistribution and radiation dosimetry of VisAcT/[18F]FAraG in cancer patients selected for immunotherapy. Each patient may have up to two PET(Positron Emission Tomography) imaging sessions - a baseline image and a scan post start of immunotherapy.

Completed Studies:

Healthy volunteers to study kinetics, dosimetry and safety of VisAcT: Prinicpal Investigator - Dr. Henry VanBrocklin at UCSF
The goal of this study was to visualize biodistribution of VisAcT/[18F]F-AraG through time in healthy human volunteers.